로딩 중…
지수 로딩 중…
차백신연구소
261780· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩2,580-4.44%
2026-06-19
Price Chart
차백신연구소-13.42%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 69.44B KRW |
| Revenue | 158.6M KRW |
| Net Income | -15.54B KRW |
| Total Assets | 21.99B KRW |
| Net Assets | 9.59B KRW |
| Employees | 56 |
| Value | |
| P/B | 7.24x |
| P/S | 437.76x |
| FCF Yield | -16.03% |
| Profitability | |
| ROE | -162.06% |
| ROA | -70.68% |
| Op. Margin | -8558.60% |
| Revenue Growth | -57.21% |
| Financial Health | |
| Debt Ratio | 229.26% |
| Total Debt | 5.92B KRW |
| FCF | -11.13B KRW |
| Cash | 2.23B KRW |
| Current Ratio | 1.82x |
| Performance | |
| 1Y Return | -13.42% |
| 1M Return | -19.75% |
| From 52W High | -61.61% |
| 1Y MDD | -57.46% |
| Trading | |
| Volume | 509,263 shares |
| Foreign Own. | 0.00% |
| Per Share | |
| EPS | -579 KRW |
| BPS | 357 KRW |
Company Info
CHA Vaccine Institute, a bio venture company established in 2000, joined the CHA Hospital/CHA Bio Group in 2011 when CHA Biotech became its largest shareholder. Utilizing its independently developed immune-enhancing platform technology, the company is developing next-generation vaccines, including therapeutic vaccines for chronic Hepatitis B, and anti-cancer immunotherapeutics. Its immune enhancers boost immune responses to vaccine antigens; specifically, Lipo-pam® is ideal for therapeutic vaccine development due to its ability to induce strong cellular immune responses. CHA Vaccine Institute is headquartered in Seongnam-si, Gyeonggi-do.